Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
Health Technology Assessment Comparative Effectiveness Europe

Mandatory Joint Clinical Assessments For EU HTAs May Be ‘Counterproductive’

  • Analysis

Executive Summary

The mandatory joint clinical assessments that the European Commission recently proposed for EU member states will be counterproductive if the highest standards of evaluation are not met, warns Health Action International.

You may also be interested in...



Industry Welcomes Mandatory EU Joint Clinical Assessments For HTA

Draft proposals to improve EU-wide cooperation on health technology assessments, including mandatory joint clinical assessments, have won support from EFPIA, the European Federation of Pharmaceutical Industries and Associations.

Success For Dutch Parallel Registration and Reimbursement Pilot

A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.

Constitutional Complaints In Germany Cast Doubt Over Fate Of UPC

The UK’s withdrawal from the EU could upset the Unitary Patent Court project.

Table

View full table

Topics

Tags:
Health Technology Assessment Comparative Effectiveness Europe
UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By